Category: InSite Vision Inc.
A clutch of medical device companies goes on a merger & acquisition spree.
InSite Vision narrowly wins affirmation of a patent infringement win against the University of California, San Francisco, in a battle over eye infection treatment.
InSite Vision (OTC:INSV) eked out a narrow win against the University of California in San Francisco in a patent battle over eye treatment.
Angeion makes up for sagging European sales by focusing on group purchasing organizations and service revenues in Q1; also, Natus Medical's earnings plunge; Mindray posts big boosts to top, bottom lines; iCad narrows quarterly losses; MiMedx sales soar in 2011; InSite's sales slide, losses widen; Exactech's bottom line shrinks; Viking boosts sales, widens losses; MedPro cuts losses; and Alphatec dives deeper into the red.
Angeion Corp. (NSDQ:ANGN) narrowed its 1st-quarter losses despite flat sales for the 3 months ended Jan. 31.
Although dragged down by a tough European climate, focusing on group purchasing organization and service revenues kept the company's sales from sliding, the cardiorespiratory diagnostic systems maker said.
Philips sues Zoll a second time over its automated external defibrillator technology, this time with a new clutch of patents.
Philips Healthcare (NYSE:PHG) plans to go another round with Zoll Medical Corp. (NSDQ:ZOLL) over automated external defibrillators, suing Zoll in Washington state over a new string of allegedly infringed patents.
Philips wants a jury to issue an injunction to keep Zoll from selling its AED Plus and AED Pro devices, as well as compensation for lost sales and legal fees.
Former president & CEO Richard Meelia decides to say goodbye to Covidien and step down from its board of directors.
Former Covidien (NYSE:COV) president & CEO Richard Meelia decided not to stand for re-election as chairman of the med-tech maker's board.
Meelia agreed to serve as a non-executive chairman of the Mansfield, Mass-based med-tech titan for a year after his retirement last July.
Dr. Samuel DeMaio escapes seven of eight lawsuits accusing him of implanting unnecessary coronary stents with his right to practice intact; also, ArthroCare to settle class-action suit for $74M; InSite Vision touts patent win; and a PE firm says UBS "mumbo-jumbo" can't conceal role in MediCor Ponzi scheme.
Dr. Samuel DeMaio
A Texas doctor accused of unnecessary stenting has slipped three of four trials against him with his license to practice in the Lone Star State intact.
Dr. Samuel DeMaio, accused last year of standard-of-care violations related to nine patients who allegedly received un-needed stents, angiograms and ICD implants, had pushed for a trial after mediation efforts with the Texas Medical Board collapsed.
Shares of Greatbatch Inc. are up after the med-tech giant's third-quarter earnings beat Wall Street's expectations; plus, ERT's profits slide in Q3; InSite's earnings in the green compared to 2010 Q3 numbers; Cardica loses big in first quarter, 25 percent drop in sales; Endologix still in red after 33 percent revenue growth for Q3; Uroplasty Q2 profits down despite 53 percent increase in sales; LeMaitre Q3 reports loss of profits even with increased revenue; Align lands great Q3 with a 14.6 percent increase of bottom line.
Greatbatch Inc. (NYSE:GB) shares are up today after the med-tech giant's third-quarter earnings beat analysts' expectations.
Clarance, N.Y.-based Greatbatch said third-quarter profits were $6.99 million, or 30 cents a share, on sales of $131 million for the three months ending Sept. 30, up 17.2 percent and 3.3 percent, respectively, compared with the same period last year.